In conclusion, LINC01123 has emerged as a newly identified and dysregulated cancer-associated lncRNA, highlighting its potential as both a promising biomarker and a key player in multiple critical aspects of tumor progression, metabolism, immune evasion, and therapeutic resistance. This evidence concerns the gene LINC01123 and neoplasm.